Literature DB >> 16786229

Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance.

Jennifer L Donovan1, Julie A Drake, Peter Whittaker, Maichi T Tran.   

Abstract

BACKGROUND: The dangers of thrombosis are well known and yet current therapy presents a paradox; effective methods of pharmacological anticoagulation are available, but underemployed. The risks associated with the use of anticoagulants, especially warfarin, and the requirement of meticulous dosing with subsequent vigilant monitoring provides some explanation for this discrepancy. Efforts have been made to address this incongruity and increase anticoagulation treatment while mitigating complications; these include the development of dosing nomograms, patient self-monitoring of anticoagulation status, and increased pharmacist participation in anticoagulation management. Although the latter option has proven effective in outpatient clinics, its in-hospital application has received less attention. Therefore, our primary goal was to review the published literature to evaluate the efficacy of in-hospital, pharmacy-managed anticoagulation. In addition, our secondary goals were to assess the potential financial benefit and community acceptance of such pharmacist management.
METHODS: Potentially relevant studies were identified by searching PubMed; however, because some pharmacy journals are not included in this database, we also used internet search engines to locate articles. We subsequently employed the Science Citation Index to find additional papers that had referenced articles identified by our initial searches.
RESULTS: Several pilot studies, focusing primarily on adherence to warfarin dosing guidelines, found general equivalence between pharmacist and physician management and specifically illustrated the potential benefit gained simply through adherence to protocols. Nevertheless, these studies frequently lacked appropriate statistical analysis and examined small, and often heterogeneous, patient groups. Larger comparative studies also possessed some of the same flaws; however, taken together the equivalence and, in some cases improvement, in patient outcomes (e.g., greater control of International Normalized Ratios and decreased length of hospital stay) that they demonstrated suggest the value of increased pharmacist participation in anticoagulation therapy. Studies using heparin-based anticoagulation reported similar positive findings and hence support the warfarin results. Both published studies examining financial implications of in-hospital pharmacy management indicated potential for considerable savings. Finally, although we identified no in-hospital studies of community acceptance, positive survey results indicted that the majority of physicians and patients accepted pharmacy-managed outpatient anticoagulation.
CONCLUSIONS: The reported outcomes of pharmacy-managed in-hospital anticoagulation therapy appear at least equal, and sometimes superior, to those obtained through standard care; however, the lack of large well-designed trials prevents drawing definitive conclusions. Nevertheless, the continued and likely increased future need for anticoagulation in general and warfarin therapy in particular suggests that increased pharmacist involvement could enhance the quality of patient care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786229     DOI: 10.1007/s11239-006-8328-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  37 in total

1.  Pharmacist involvement with warfarin dosing for inpatients.

Authors:  C Boddy
Journal:  Pharm World Sci       Date:  2001-02

2.  A pharmacist-managed anticoagulation clinic: six-year assessment of patient outcomes.

Authors:  Michelle L Willey; Larisa Chagan; Thomas S Sisca; Kevin J Chapple; A Kevin Callahan; Judy L Crain; Larissa E Kitenko; Theresa Martin; Kimberly D Spedden
Journal:  Am J Health Syst Pharm       Date:  2003-05-15       Impact factor: 2.637

3.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

4.  Development and implementation of a pharmacist-managed inpatient warfarin protocol.

Authors:  David L Damaske; Robert W Baird
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

5.  Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy.

Authors:  R F Ellis; M A Stephens; G B Sharp
Journal:  Am J Hosp Pharm       Date:  1992-02

6.  Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation.

Authors:  Ahmed H Abdelhafiz; Nigel M Wheeldon
Journal:  Am J Geriatr Pharmacother       Date:  2003-12

7.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

8.  Therapeutic heparin monitoring service in a small community hospital.

Authors:  S J Pawloski; P L Kersh
Journal:  Hosp Pharm       Date:  1992-08

9.  The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic disease.

Authors:  Alex C Spyropoulos; William Haire
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 10.  The future of anticoagulation clinics.

Authors:  B Gail Macik
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

View more
  15 in total

1.  Inpatient warfarin management: pharmacist management using a detailed dosing protocol.

Authors:  Nancy L Dawson; Ivan E Porter; Dusko Klipa; William R Bamlet; Mary Ann Hedges; Michael J Maniaci; Jason Persoff; Archana Roy; Alden V Patel
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

Review 2.  Role of the anticoagulant monitoring service in 2018: beyond warfarin.

Authors:  Nathan P Clark
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge.

Authors:  Nibal Chamoun; C Gabriela Macías; Jennifer L Donovan; Robert Klugman; Joel Gore; Pascale Salameh; Maichi T Tran
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 4.  The future of inpatient anticoagulation management.

Authors:  Allison E Burnett; Toby C Trujillo
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 5.  Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns.

Authors:  Nancy Nkansah; Olga Mostovetsky; Christine Yu; Tami Chheng; Johnny Beney; Christine M Bond; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

6.  Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum.

Authors:  Edith A Nutescu; Ann K Wittkowsky; Allison Burnett; Geno J Merli; Jack E Ansell; David A Garcia
Journal:  Ann Pharmacother       Date:  2013-04-12       Impact factor: 3.154

Review 7.  Impact on patient care: patient case through the continuum of care.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

8.  Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital.

Authors:  Subramaniam Thanimalai; Asrul Akmal Shafie; Mohamed Azmi Hassali; Jeyaindran Sinnadurai
Journal:  Int J Clin Pharm       Date:  2013-05-29

9.  Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey.

Authors:  Hazem F Elewa; Christina E DeRemer; Kimble Keller; Jaspal Gujral; Thomas V Joshua
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

10.  Feasibility of ASsisTed WARfarin Dosing by Clinical Pharmacy Support Assistants (FAST-WARD Study).

Authors:  Damen Man; Vincent H Mabasa
Journal:  Can J Hosp Pharm       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.